A phase I double-blind, randomised study of Motrem (LR-12) in healthy volunteers

Trial Profile

A phase I double-blind, randomised study of Motrem (LR-12) in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs LR 12 (Primary)
  • Indications Myocardial infarction; Septic shock
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 26 Sep 2016 New trial record
    • 13 Sep 2016 Results published in the Media Release
    • 13 Sep 2016 According to an Inotrem media release, the results of the study will be released on December 6, 2016 at the next International Sepsis Forum in Paris and published in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top